Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus HAIC-FOLFIRI in unresectable hepatocellular carcinoma after failure of HAIC-FOLFOX + TKI + PD-1
ChiCTR2500113650Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500113650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113650.